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Introduction: B Acute Lymphoblastic Leukemia 
B acute lymphoblastic leukemia (ALL) is a cancer that affects the early white blood-forming cells in bone marrow. Chemotherapy treatment only 
achieves 33% survival rate in adult ALL , far from the 90% seen in children.  
Immunotherapy has a great potential for the treatment of lymphomas and leukemias by redirecting T cells specificity to a tumor-associated antigen 
(TAA).The constructions that allow TAA recognition by T cells are called single chain antigen receptors (CARs). 
Objectives 
• Understand the basic molecular mechanisms of CAR therapy. 
• Analyze the different variables present in clinical trials. 
• Analyze the efficacy of CAR-engineered T cells in the ALL treatment. 
• Explain the possible toxicities and the  future challenges to improve 
CAR therapy. 
Methodology 
 Scientific literature search on PubMed based on specific words such 
as: CAR T Therapy, immunotherapy, lymphodepleting.  
 Scientific literature search on specialized books. 
  Interview done to Dr. Sonia Guedan, specialist in CAR therapy. 
 
CAR structure 
 Exodomain: it consists in the single-chain fragment variable (scFV) and it provides specificity 
to CAR. Derived from a murine monoclonal Ab that links to a TAA independent of the MHC. 
 Transmembrane domain: such as CD8. 
 Endodomain: which activates T cells. It includes cytoplasmatic domains that transmit 
activation signals such as CD3, CD28 or 4-1BB. The CARs can include more than one activation 
domain and it results in first-, Second- and third-generation CARs. 
 
 
 
 
 
 
 
 
 
 
 
Gene modification of T cells 
 Virus Vector-based approaches: using gammaretrovirus or 
lentivirus. 
CAR retroviral vector: 
 
 Non virus-based approaches: random Integration with 
electroporation or transposon-based Integration. 
Tumor-associated antigen 
 CD19: highly expressed on B cells, both malignant and normal. It’s 
the most TAA used in CAR therapy. 
 CD22: also expressed on B cells. It could be useful in case of 
immune escape with CD19-blasts. 
 Others: CD20, ROR1. 
Prior Conditioning chemotherapy 
Most of the clinical trials use prior Conditioning chemotherapy, which include y-irradiation or 
cyclophosphamide. It is used before CAR T cell infusion for two reasons.  
 
 
 
 
 
Although it’s clearly demonstrated in pre-clinical and clinical trials that prior conditioning 
chemotherapy provides better results it is still being studied which one of this two factors is more 
relevant and which kind of conditioning chemotherapy is more effective. 
     
                    
Lymphodepleting eliminate endogenous 
T cells that compete with transferred CAR 
cells for cytokines. 
Lymphodepleting reduces tumor mass 
prior to CAR-modified T cell infusion 
Patients with relapsed-ALL could present resistance to conditioning 
chemotherapy as they were treated before with chemotherapy 
Principle of CAR therapy 
Conclusions 
 Clinical Trials using CAR therapy are in phase I and II and the most used TAA is 
CD19. There is a high interest in other TAAs as CD22. 
 
 Conditioning therapy has a great importance in CAR therapy results. 
 
 The main limitations of this technique are: 
 The short-follow up post T cell infusion when it has to be done an 
allogenic stem cell transplantation. 
 The relatively small among of patients treated until now. 
 
 The main toxicities detected are B-cell aplasia (ameliorated by infusing 
immunoglobulin), liver toxicity (difficult to correct) and cytokine storm 
(ameliorated by introducing antibodies blocking  TNF and IL-6). 
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Institution UPenn NCI 
Patient population -Relapsed/refractory ALL 
-N=30 
-Age 5-60 years old 
-Detectable disease before CAR infusion 
N=24 .MRD-(minimal residual disease) 
N=5 
-Morphologic remission, MRD not 
assessed, N=1 
-Relapsed/refractory ALL 
-N=21  
-Age 1-30 years old 
-Detectable disease 
before CAR infusion, 
N=21 
Patients who had failed 
prior alloHCT 
N=18 of 30 N=8 of 21 
Lymphodepletion 
before CAR 
Variable  Fludarabine/cyclophosph
amide 
CAR-signaling 
endodomain 
CD137+CD3 CD28+CD3 
Gene transfer approach Lentivirus Retrovirus 
Persistence of CAR-T 
cells 
Up to 2 years with continued follow-up 
  
No CARs detected after 
day 68 
Response CR/CRi(N=27)=90% 
MRD-ve(N=22)=73% 
(Median follow-up; 7 months) 
CR/CRi(N=14)=70% (B 
ALL) 
MRD-ve 
(N=12)=60%(BALL) 
(Median follow-up 10 
months) 
Clinical trial results with CD19-specific CAR+ T  
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